Pricing Log in Create free account
Friday 6 November 2026 Export PETV’s income statement to Excel — free account

PetVivo Holdings, Inc.

PETV Healthcare Medical Devices

PetVivo Holdings, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, up 0.80% from fiscal 2025.

Revenue
+13.5%
EPS
+44.4%
Free cash flow
+40.1%

Quarter to June 2026, against a year earlier

0.63 0.01 +1.61%
Market cap
$12.9M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
3/9
Altman Z
−38.64
Beneish M
−8.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.21
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 2 — 1 1 — 1 — 1 —
Sell — — — — — — — — — — — —
Insider Ownership 68.02%

Capital & Financial Ratios $m

Size
Market Cap 12.93
Revenue ttm 1.18
Net income ttm (9.78)
Free cash flow ttm (5.45)
Net debt Q (0.12)
Valuation
P/E 0.00
Forward P/E (1.22) (negative: loss-making)
Price / sales 19.76 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 17.28 (above 6: high)
Financial health
Current ratio Q 0.72 (below 1: weak)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (321.76)
Growth
Revenue growth Q +13.48% (above 0%: growing)
Operating income growth Q +12.77% (above 0%: growing)
EPS, this year −14.12% (below 0%: weak)
EPS, next year A +35.05% (at or above 15%: strong)
Revenue, next year A +818.76% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 19.7×, against a ten-year median of 112×; over the ten years it ranged from 7.4× in 2024 to 8,210× in 2020.
P/S against its own 10 years 19.80%
10-year low 10-year high
P/B against its own 10 years 60.09%
10-year low 10-year high
EV/Sales against its own 10 years 19.84%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 0 0 0 0
Receivables 0 4 1 0
Inventory 0 0 1 0
Other — — — —
1 6 2 1
2024 2025 2026 Q'26
Payables 1 1 1 0
ST’ Debt — — — —
Other — 0 — —
1 4 1 1

Compound Annual Growth %

10y 5y 3y
Sales — 146.28% 7.57%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (17.58%) 0.00% 44.76%

EPS $

Jun Sep Dec Mar Year
’26 (0.05) — — — —
’26 (0.09) (0.11) (0.07) (0.11) (0.38)
’25 (0.11) (0.11) (0.09) (0.11) (0.41)
’24 (0.25) (0.28) (0.12) (0.14) (0.78)
’23 (0.20) (0.21) (0.23) (0.21) (0.85)
’22 (0.07) (0.13) (0.17) (0.25) (0.57)
’21 (0.16) (0.23) (0.16) (0.04) (0.57)
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 0 — — — —
’26 0 0 0 0 1
’25 0 0 1 0 1
’24 0 0 1 0 1
’23 0 0 1 0 1
’22 0 0 0 0 0
’21 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) — — — —
’26 (2) (2) (1) (1) (6)
’25 (2) (2) (1) (1) (5)
’24 (2) (2) (1) (2) (7)
’23 (2) (2) (2) (1) (7)
’22 0 (1) (1) (2) (4)
’21 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) — — — —
’26 (2) (2) (1) (1) (6)
’25 (2) (2) (1) (2) (6)
’24 (2) (2) (1) (2) (8)
’23 (2) (2) (2) (1) (7)
’22 0 (1) (1) (2) (4)
’21 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jun ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 0 0 — 0 0 0 1 1 1 1 1 +75.8% — — — —
Gross margin, % 100.00 100.00 0.00 (447.22) 15.08 (74.05) 75.89 89.49 87.85 66.12 66.97 (33.9) pt
EBT (17) (2) (5) (2) (4) (5) (9) (11) (8) (10) (10) (4.9%)
EBT margin, % (232,700.00) (155,820.00) 0.00 (57,852.78) (27,958.73) (4,338.24) (950.46) (1,130.93) (741.65) (917.46) (827.33) +231,782.5 pt
Net income (17) (2) (5) (2) (4) (5) (9) (11) (8) (10) (10) (4.9%)
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.01 0.09 0.07 0.06 0.04 0.03 +30.3%
Earnings (7.68) (0.65) (1.00) (0.38) (0.57) (0.57) (0.85) (0.78) (0.41) (0.38) (0.34) (28.4%)
Cash flow (0.07) (0.15) (0.16) (0.09) (0.12) (0.48) (0.66) (0.53) (0.26) (0.20) (0.15) +12.4%
Capex (0.02) (0.01) (0.02) (0.01) (0.03) (0.02) (0.04) (0.02) (0.03) 0.00 0.00 (43.9%)
Free cash flow (0.09) (0.16) (0.18) (0.11) (0.15) (0.50) (0.71) (0.55) (0.29) (0.20) (0.15) +9.6%
Book value 0.41 0.04 (0.18) (0.20) (0.14) 0.68 0.07 0.05 0.21 0.07 0.04 (17.4%)
Shares, m 2 4 5 5 6 9 10 14 20 30 32 +35.1%
Valuation, ×
Valuation, × P/E 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 505.14 6,635.64 — 509.75 5,165.58 154.60 30.65 14.42 10.86 18.49 19.76 1,449.5
P/B 4.38 179.74 — 0.00 0.00 2.99 38.78 20.36 2.92 9.62 17.28 28.8
EV/Sales 511.79 6,591.12 — 583.77 5,182.36 102.05 30.40 14.35 10.53 18.32 19.66 1,449.4
EV/FCF (3.54) (24.01) — (5.26) (70.41) (2.69) (3.85) (1.79) (2.02) (3.14) (3.89) (13.0)
Cash, $m
Cash, $m Operating cash flow 0 (1) (1) 0 (1) (4) (7) (7) (5) (6) (5) +51.8%
Capex 0 0 0 0 0 0 0 0 (1) 0 0 (24.5%)
Free cash flow 0 (1) (1) (1) (1) (4) (7) (8) (6) (6) (5) +48.0%
Balance, $m
Balance, $m Working capital (1) (1) (1) (1) (1) 6 0 0 1 0 0 n/m
Net debt 0 0 0 0 0 (6) 0 0 0 0 0 n/m
Shareholders’ equity 1 0 (1) (1) (1) 6 1 1 4 2 1 +11.6%
Returns, %
Returns, % ROA (167.13) (134.92) (421.25) (343.23) (518.94) (121.39) (176.71) (394.48) (134.88) (168.43) (214.99) (1.3) pt
ROIC (834.44) (1,545.79) 0.00 0.00 0.00 0.00 (1,115.10) (1,085.05) (130.88) (306.41) (447.24) +528.0 pt
ROE (193.78) (488.82) 1,343.63 221.45 364.45 (197.06) (259.77) (1,552.84) (343.02) (339.61) (405.06) (145.8) pt
People
People Employees — — — — 2 15 25 20 24 22 — +61.5%
Revenue/emp, $m 0.00 0.00 — 0.00 0.01 0.01 0.04 0.05 0.05 0.05 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

PetVivo Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CTSO Cytosorbents Corporation $14.5M — (loss-making) — (loss-making) +0.17% (above 0%: growing) n/m +64.90% (above 0%: growing) 73.18% (27.39%) Compare
RBOT Vicarious Surgical Inc. $14.3M — (loss-making) — — n/m +47.33% (above 0%: growing) 0.00% 0.00% Compare
HSCS HeartSciences Inc. $13.3M — (loss-making) — (loss-making) −46.15% (below 0%: shrinking) n/m +18.18% (above 0%: growing) 61.90% (139,957.14%) Compare
PETV PetVivo Holdings, Inc. $12.9M — (loss-making) — (loss-making) +13.48% (above 0%: growing) n/m +40.13% (above 0%: growing) 66.14% (476.54%)
ITOC iTonic Holdings Ltd. $12.4M — — — — — — — Compare
PAVM PAVmed Inc. $12.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%) Compare
MODD Modular Medical, Inc. $12.2M — (loss-making) — — n/m −5.61% (below 0%: shrinking) 0.00% 0.00% Compare
IRIX IRIDEX Corporation $11.9M — (loss-making) — (loss-making) −7.41% (below 0%: shrinking) n/m +130.24% (above 0%: growing) 34.19% (8.19%) Compare
SINT SINTX TECHNOLOGIES, INC. $11.5M — (loss-making) — (loss-making) +952.88% (above 0%: growing) n/m +47.37% (above 0%: growing) 62.19% (74.66%) Compare
Median of peers $12.4M — — +0.17% — +47.33% 34.19% (27.39%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 3 October 2023

Ownership

Directors and executive officers, together 20.10%
Allan Sarroff 11.49%
John Lai 8.83%
Stanley Cruden 8.00%
David B. Masters 5.41%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

PetVivo Holdings, Inc. (PETV) Latest News

15 Oct

Impact 3 · · GlobeNewswire

22 Sep

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

20 Aug

Impact 3 ·

18 Aug

Impact 3 · transcript

14 Aug

Impact 3 ·

14 Jul

Impact 3 ·

1 Jul

Impact 3 ·

29 Jun

Impact 3 ·

24 Jun

Impact 4 · · GlobeNewswire

18 Feb

Impact 4 · · GuruFocus.comZacksMotley FoolMarketBeat

17 Feb

Impact 4 · · GlobeNewswireMotley FoolMotley FoolMarketBeatMotley FoolMobyMotley FoolMotley Fool

7 Feb

Impact 3 · · ACCESS Newswire

31 Jan

Impact 3 · · ACCESS Newswire

21 Jan

Impact 4 · · GlobeNewswire

14 Jan

Impact 3 · · ACCESS Newswire

27 Dec

Impact 3 · · ACCESS Newswire

23 Dec

Impact 3 · · ACCESS Newswire

10 Dec

Impact 3 · · ACCESS Newswire

25 Nov

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswireGuruFocus.com24/7 Wall St.MT NewswiresMT NewswiresMT NewswiresSimply Wall St.

17 Nov

Impact 4 · · GuruFocus.com
Impact 4 · · GlobeNewswire

14 Nov

Impact 4 · · GlobeNewswire
Impact 4 · · 24/7 Wall St.

12 Nov

Impact 3 ·

28 Oct

Impact 3 · · GlobeNewswireBenzingaSimply Wall St.

27 Oct

Impact 3 · · NewMediaWire

21 Oct

Impact 4 ·

16 Oct

Impact 4 · · GlobeNewswireMT NewswiresZacksInsider MonkeyMT NewswiresMT NewswiresPharmaceutical TechnologySimply Wall St.
stockrow.com/PETV · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com